| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Meeting Report |
Department of Pharmacology and Simmons Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas 75390 [P. E. T.]; Oxigene Inc., Boston, Massachusetts 02472 [D. J. C.]; and Cancer and Infection Bioscience Department, AstraZeneca, Alderley Park, Macclesfield, Cheshire SK10 4TG, United Kingdom [D. C. B.]
ABSTRACT
The First International Conference on Vascular Targeting focused on vascular targeting agents (VTAs) that occlude or destroy the pre-existing blood vessels of solid tumors. The VTAs cause a rapid shutdown in the blood supply to the tumor that kills tumor cells by depriving them of oxygen and nutrients. The VTAs are distinct from antiangiogenic agents, which prevent new blood vessel formation. Two major types of VTAs are being developed for cancer: the ligand-directed VTAs that use antibodies, peptides, and growth factors to deliver toxins, procoagulants, and proapoptotic effectors to tumor endothelium, and the small molecule VTAs that do not specifically localize to tumor endothelium but exploit pathophysiological differences between tumor and normal tissue endothelia to induce acute vascular shutdown in tumors. Both approaches were described at the meeting and highlighted the variety of VTAs in preclinical development, their selectivity for tumor endothelium, their rapid antitumor effects, and the improved activity seen when combined with other anticancer approaches (antiproliferative chemotherapeutic drugs, radiation, radiolabeled antibodies, nitric oxide synthetase inhibitors, and antiangiogenic agents). Early clinical studies were summarized for the small molecule VTAs: the antitubulin drugs, combretastatin A4 phosphate (CA4P) and ZD6126, and the flavonoid, 5,6-dimethylxanthenone-4-acetic acid (DMXAA). The agents lacked the bone marrow and gastrointestinal toxicities associated with antiproliferative chemotherapy. As a marker of biological effect, blood flow reductions in tumors were measured using magnetic resonance imaging or positron emission tomography for all of the agents tested, and single-agent clinical activity was seen. These agents are now being evaluated in combined modality studies to see whether the impressive results obtained in experimental models can be translated into humans.
This article has been cited by other articles:
|
|
 |
|
  A. Fleischmann, B. Waser, and J. C. Reubi High expression of gastrin-releasing peptide receptors in the vascular bed of urinary tract cancers: promising candidates for vascular targeting applications Endocr. Relat. Cancer, June 1, 2009; 16(2): 623 - 633. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Gould, F. R. Westwood, J. O. Curwen, S. E. Ashton, D. W. Roberts, S. C. Lovick, and A. J. Ryan Effect of Pretreatment With Atenolol and Nifedipine on ZD6126-Induced Cardiac Toxicity in Rats J Natl Cancer Inst, November 21, 2007; 99(22): 1724 - 1728. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Atri New Technologies and Directed Agents for Applications of Cancer Imaging J. Clin. Oncol., July 10, 2006; 24(20): 3299 - 3308. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. P. Hall, F. R. Westwood, and P. F. Wadsworth Review of the Effects of Anti-Angiogenic Compounds on the Epiphyseal Growth Plate Toxicol Pathol, February 1, 2006; 34(2): 131 - 147. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Dong, B. Ko, P. Baumeister, S. Swenson, F. Costa, F. Markland, C. Stiles, J. B. Patterson, S. E. Bates, and A. S. Lee Vascular Targeting and Antiangiogenesis Agents Induce Drug Resistance Effector GRP78 within the Tumor Microenvironment Cancer Res., July 1, 2005; 65(13): 5785 - 5791. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Taraboletti, G. Micheletti, R. Dossi, P. Borsotti, M. Martinelli, F. Fiordaliso, A. J. Ryan, and R. Giavazzi Potential Antagonism of Tubulin-Binding Anticancer Agents in Combination Therapies Clin. Cancer Res., April 1, 2005; 11(7): 2720 - 2726. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K Gupta and J Zhang Angiogenesis: a curse or cure? Postgrad. Med. J., April 1, 2005; 81(954): 236 - 242. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. C. Thoeny, F. De Keyzer, F. Chen, Y. Ni, W. Landuyt, E. K. Verbeken, H. Bosmans, G. Marchal, and R. Hermans Diffusion-weighted MR Imaging in Monitoring the Effect of a Vascular Targeting Agent on Rhabdomyosarcoma in Rats Radiology, March 1, 2005; 234(3): 756 - 764. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Rehman and G. C. Jayson Molecular Imaging of Antiangiogenic Agents Oncologist, February 1, 2005; 10(2): 92 - 103. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Kasibhatla, H. Gourdeau, K. Meerovitch, J. Drewe, S. Reddy, L. Qiu, H. Zhang, F. Bergeron, D. Bouffard, Q. Yang, et al. Discovery and mechanism of action of a novel series of apoptosis inducers with potential vascular targeting activity Mol. Cancer Ther., November 1, 2004; 3(11): 1365 - 1374. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. A. Horner, S. Gould, J. P. Noakes, N. J. Rattray, S. L. Allen, E. Zotova, and J. C. Arezzo Lack of neurotoxicity of the vascular targeting agent ZD6126 following repeated i.v. dosing in the rat Mol. Cancer Ther., July 1, 2004; 3(7): 783 - 791. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. L. Evelhoch, P. M. LoRusso, Z. He, Z. DelProposto, L. Polin, T. H. Corbett, P. Langmuir, C. Wheeler, A. Stone, J. Leadbetter, et al. Magnetic Resonance Imaging Measurements of the Response of Murine and Human Tumors to the Vascular-Targeting Agent ZD6126 Clin. Cancer Res., June 1, 2004; 10(11): 3650 - 3657. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Sonveaux, C. Dessy, P. Martinive, X. Havaux, B. F. Jordan, B. Gallez, V. Gregoire, J.-L. Balligand, and O. Feron Endothelin-1 Is a Critical Mediator of Myogenic Tone in Tumor Arterioles: Implications for Cancer Treatment Cancer Res., May 1, 2004; 64(9): 3209 - 3214. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Holig, M. Bach, T. Volkel, T. Nahde, S. Hoffmann, R. Muller, and R. E. Kontermann Novel RGD lipopeptides for the targeting of liposomes to integrin-expressing endothelial and melanoma cells Protein Eng. Des. Sel., May 1, 2004; 17(5): 433 - 441. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. E. Thorpe Vascular Targeting Agents as Cancer Therapeutics Clin. Cancer Res., January 15, 2004; 10(2): 415 - 427. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G M Tozer Measuring tumour vascular response to antivascular and antiangiogenic drugs Br. J. Radiol., December 1, 2003; 76(suppl_1): S23 - S35. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Q.-T. Le and A. J. Giaccia Therapeutic Exploitation of the Physiological and Molecular Genetic Alterations in Head and Neck Cancer Clin. Cancer Res., October 1, 2003; 9(12): 4287 - 4295. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Collins Functional Imaging in Phase I Studies: Decorations or Decision Making? J. Clin. Oncol., August 1, 2003; 21(15): 2807 - 2809. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
